Skip to Content

t(9;22)(q34;q11.2);BCR-ABL1, Quantitative Transcript Analysis

Real-Time and Nested PCR

Indication

Detection of the t(9;22)(q34;q11.2);BCR-ABL1 fusion transcript for diagnosis and monitoring of residual disease in patients with chronic myelogenous leukemia (CML), B-lymphoblastic leukemia (B-ALL) with t(9;22) and a small subset of patients with acute myeloid leukemia  (AML).

Methodology

RNA is extracted from white blood cells in bone marrow and/or peripheral blood and reverse transcribed to cDNA. Real-time PCR is performed to amplify the BCR-ABL transcripts as well as ABL transcripts. Transcript types b3a2, b2a2 and e1a2 are detected in single tube reaction.

Test Parameters

Sensitivity is approximately one in 100,000 for real-time PCR. Levels detected in peripheral blood and bone marrow samples are generally equivalent.

Turnaround Time

Five to 10 working days

Sample Requirements

  • 10-30 ml peripheral blood in lavender top (EDTA) tube, sent on wet ice

    or
  • 2-5 ml of bone marrow aspirate in lavender top (EDTA) tube, sent on wet ice

CPT Codes

81206, 81207, 81208

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center